Emerging Therapeutics for Ocular Surface Disease

[1]  Jason K. Lee,et al.  Omalizumab as single-dose therapy for vernal keratoconjunctivitis. , 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[2]  L. Gentilucci,et al.  DS‐70, a novel and potent α4 integrin antagonist, is an effective treatment for experimental allergic conjunctivitis in guinea pigs , 2018, British journal of pharmacology.

[3]  Luis Santamaría,et al.  [Long-term efficacy of omalizumab in patients with conventional treatment-resistant vernal keratoconjunctivitis]. , 2018, Revista alergia Mexico.

[4]  R. Giuffrida,et al.  Comparison of the efficacy of 0.03% tacrolimus eye drops diluted in olive oil and linseed oil for the treatment of keratoconjunctivitis sicca in dogs. , 2018, Arquivos brasileiros de oftalmologia.

[5]  Hyun Soo Lee,et al.  TRPV1 Antagonist Suppresses Allergic Conjunctivitis in a Murine Model , 2018, Ocular immunology and inflammation.

[6]  Narendra P. Datti,et al.  Topical Olopatadine Hydrochloride versus Ketotifen Fumarate for Allergic Conjunctivitis , 2018, Journal of ophthalmic & vision research.

[7]  C. Phan,et al.  A Rapid Extraction Method to Quantify Drug Uptake in Contact Lenses , 2018, Translational vision science & technology.

[8]  M. Cavet,et al.  Brimonidine Ophthalmic Solution 0.025% for Reduction of Ocular Redness: A Randomized Clinical Trial , 2018, Optometry and vision science : official publication of the American Academy of Optometry.

[9]  S. Geschwindner,et al.  Discovery of a Novel Oral Glucocorticoid Receptor Modulator (AZD9567) with Improved Side Effect Profile. , 2018, Journal of medicinal chemistry.

[10]  J. Mehta,et al.  A Biodegradable, Sustained-Released, Tacrolimus Microfilm Drug Delivery System for the Management of Allergic Conjunctivitis in a Mouse Model. , 2018, Investigative Ophthalmology and Visual Science.

[11]  H. DeCory,et al.  Evaluation of Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution, 0.025% for Treatment of Ocular Redness , 2018, Current eye research.

[12]  J. Oh,et al.  Topical Tacrolimus 0.03% for Maintenance Therapy in Steroid-Dependent, Recurrent Phlyctenular Keratoconjunctivitis , 2017, Cornea.

[13]  A. Lambiase,et al.  Allergic conjunctivitis: current concepts on pathogenesis and management. , 2018, Journal of Biological Regulators and Homeostatic Agents.

[14]  M. Ozaki,et al.  Efficacy of 0.05% epinastine and 0.1% olopatadine for allergic conjunctivitis as seasonal and preseasonal treatment , 2017, Clinical ophthalmology.

[15]  K. Kaarniranta,et al.  Topical cis-urocanic acid prevents ocular surface irritation in both IgE -independent and -mediated rat model , 2017, Graefe's Archive for Clinical and Experimental Ophthalmology.

[16]  Qi Wan,et al.  Therapeutic Effect of 0.1% Tacrolimus Eye Drops in the Tarsal Form of Vernal Keratoconjunctivitis , 2017, Ophthalmic Research.

[17]  F. Occasi,et al.  Vernal keratoconjunctivitis treated with omalizumab: A case series , 2017, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[18]  V. Rathi,et al.  Role of Scleral Contact Lenses in Management of Coexisting Keratoconus and Stevens–Johnson Syndrome , 2017, Cornea.

[19]  J. A. Gomes,et al.  Topical tacrolimus for the treatment of severe allergic keratoconjunctivitis in children. , 2017, Arquivos brasileiros de oftalmologia.

[20]  M. Rohani,et al.  Comparative Evaluation of Tacrolimus Versus Interferon Alpha-2b Eye Drops in the Treatment of Vernal Keratoconjunctivitis: A Randomized, Double-Masked Study , 2017, Cornea.

[21]  D. Freitas,et al.  Tacrolimus eye drops as monotherapy for vernal keratoconjunctivitis: a randomized controlled trial. , 2017, Arquivos brasileiros de oftalmologia.

[22]  Kyung-Mi Joo,et al.  Increased cis-to-trans urocanic acid ratio in the skin of chronic spontaneous urticaria patients , 2017, Scientific Reports.

[23]  E. Takamura,et al.  Steroid-Sparing Effect of 0.1% Tacrolimus Eye Drop for Treatment of Shield Ulcer and Corneal Epitheliopathy in Refractory Allergic Ocular Diseases. , 2016, Ophthalmology.

[24]  V. Perez,et al.  Emerging therapeutics for ocular surface disease , 2016, Current opinion in allergy and clinical immunology.

[25]  M. Barzegar-Jalali,et al.  Comparison of Different Nanosuspensions as Potential Ophthalmic Delivery Systems for Ketotifen Fumarate. , 2016, Advanced pharmaceutical bulletin.

[26]  A. Concheiro,et al.  Biomimetic contact lenses eluting olopatadine for allergic conjunctivitis. , 2016, Acta biomaterialia.

[27]  Anuj Chauhan,et al.  Mechanistic modeling of ophthalmic drug delivery to the anterior chamber by eye drops and contact lenses. , 2016, Advances in colloid and interface science.

[28]  Parvin Zakeri-Milani,et al.  Design of eudragit RL nanoparticles by nanoemulsion method as carriers for ophthalmic drug delivery of ketotifen fumarate , 2016, Iranian journal of basic medical sciences.

[29]  E. Heffler,et al.  Omalizumab Treatment of Vernal Keratoconjunctivitis. , 2016, JAMA ophthalmology.

[30]  Hyun Soo Lee,et al.  Topical Administration of β-1,3-Glucan to Modulate Allergic Conjunctivitis in a Murine Model. , 2016, Investigative ophthalmology & visual science.

[31]  A. Adewale,et al.  Phase 3 Randomized Double-Masked Study of Efficacy and Safety of Once-Daily 0.77% Olopatadine Hydrochloride Ophthalmic Solution in Subjects With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge Model , 2015, Cornea.

[32]  L. Pylkkänen,et al.  A randomized phase I clinical study of cis‐urocanic acid eye drops in healthy adult subjects , 2015, Acta ophthalmologica.

[33]  M. Baiula,et al.  Mapracorat, a novel non-steroidal selective glucocorticoid receptor agonist for the treatment of allergic conjunctivitis. , 2015, Inflammation & allergy drug targets.

[34]  J. Ciolino,et al.  Ocular Itch Relief with Alcaftadine 0.25% Versus Olopatadine 0.2% in Allergic Conjunctivitis: Pooled Analysis of Two Multicenter Randomized Clinical Trials , 2014, Advances in Therapy.

[35]  S. Vanzulli,et al.  Restoring conjunctival tolerance by topical nuclear factor-κB inhibitors reduces preservative-facilitated allergic conjunctivitis in mice. , 2014, Investigative ophthalmology & visual science.

[36]  P. Govoni,et al.  Mapracorat, a selective glucocorticoid receptor agonist, causes apoptosis of eosinophils infiltrating the conjunctiva in late-phase experimental ocular allergy , 2014, Drug design, development and therapy.

[37]  V. Dimov,et al.  Pharmacokinetic evaluation of topical calcineurin inhibitors for treatment of allergic conjunctivitis , 2014, Expert opinion on drug metabolism & toxicology.

[38]  E. Turkoglu,et al.  Comparative Evaluation of Olopatadine 0.01% Combined Fluorometholone 0.1% Treatment Versus Olopatadine 0.01% Combined Ketorolac 0.4% Treatment in Patients with Acute Seasonal Allergic Conjunctivitis , 2014, Current eye research.

[39]  J. Wolffsohn,et al.  Effectiveness of nonpharmacologic treatments for acute seasonal allergic conjunctivitis. , 2014, Ophthalmology.

[40]  E. Meltzer,et al.  An algorithm for the management of allergic conjunctivitis. , 2013, Allergy and asthma proceedings.

[41]  P. Arkwright,et al.  Severe vernal keratoconjunctivitis successfully treated with subcutaneous omalizumab. , 2013, Journal of AAPOS.

[42]  S. McCabe,et al.  Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference , 2012, Clinical ophthalmology.

[43]  R. Cardona,et al.  Omalizumab. An option in vernal keratoconjunctivitis? , 2012, Allergologia et immunopathologia.

[44]  Alex Hui,et al.  Delivery of Ketotifen Fumarate by Commercial Contact Lens Materials , 2012, Optometry and Vision Science.

[45]  Xinghuai Sun,et al.  Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients. , 2012, Clinical therapeutics.

[46]  H. Aono,et al.  Beneficial pharmacological effects of selective glucocorticoid receptor agonist in external eye diseases. , 2011, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[47]  Francisco J. López,et al.  In vivo ocular efficacy profile of mapracorat, a novel selective glucocorticoid receptor agonist, in rabbit models of ocular disease. , 2011, Investigative ophthalmology & visual science.

[48]  S. Doan,et al.  Omalizumab for severe atopic keratoconjunctivitis , 2010, BMJ Case Reports.

[49]  L. Bielory,et al.  The epidemiology of ocular and nasal allergy in the United States, 1988-1994. , 2010, The Journal of allergy and clinical immunology.

[50]  L. Bielory,et al.  Emerging drugs for conjunctivitis , 2009, Expert opinion on emerging drugs.

[51]  A. Karalezli,et al.  Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo‐controlled environmental trial , 2009, Acta ophthalmologica.

[52]  M. Lemp,et al.  Contact lenses and associated anterior segment disorders: dry eye disease, blepharitis, and allergy. , 2008, Immunology and allergy clinics of North America.

[53]  L. Rosenwasser,et al.  Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge* , 2007, Current Medical Research and Opinion.

[54]  S. Butrus,et al.  Ocular allergy: diagnosis and treatment. , 2005, Ophthalmology clinics of North America.

[55]  Y. Tekelioğlu,et al.  Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial. , 2005, Clinical therapeutics.

[56]  B. Lanier,et al.  Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model , 2004, Current medical research and opinion.

[57]  V. Yaylalı,et al.  Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis. , 2003, Acta ophthalmologica Scandinavica.

[58]  G. Berdeaux,et al.  A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis. , 2002, Clinical therapeutics.

[59]  A. Epstein,et al.  Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model. , 2002, Clinical therapeutics.

[60]  M. Avunduk,et al.  Mechanisms and comparison of anti-allergic efficacy of topical lodoxamide and cromolyn sodium treatment in vernal keratoconjunctivitis. , 2000, Ophthalmology.

[61]  G. Ciprandi,et al.  Safety and Efficacy Comparison of Emedastine 0.05% Ophthalmic Solution Compared to Levocabastine 0.05% Ophthalmic Suspension in Pediatric Subjects with Allergic Conjunctivitis , 2000 .

[62]  M. Abelson,et al.  An Efficacy and Tolerance Comparison of Emedastine Difumarate 0.05% and Levocabastine Hydrochloride 0.05%: Reducing Chemosis and Eyelid Swelling in Subjects with Seasonal Allergic Conjunctivitis , 2000 .

[63]  A. J. Aguilar,et al.  Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate. , 2000, Acta ophthalmologica Scandinavica. Supplement.

[64]  S. L. Spector,et al.  Conjunctivitis medicamentosa. , 1994, The Journal of allergy and clinical immunology.

[65]  D. Easty,et al.  Randomised Double-Masked Trial of Lodoxamide and Sodium Cromoglycate in Allergic Eye Disease , 1992, European journal of ophthalmology.

[66]  M. Abelson,et al.  Effects of Vasocon-A in the allergen challenge model of acute allergic conjunctivitis. , 1990, Archives of ophthalmology.